Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab

MLA

Freeman, C. L., et al. Role of CD20 Expression and Other Pre-Treatment Risk Factors in the Development of Infusion-Related Reactions in Patients with CLL Treated with Obinutuzumab. 2016. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1223533793&authtype=sso&custid=ns315887.

APA

Freeman, C. L., Dixon, M., Houghton, R., Kreuzer, K.-A., Fingerle-Rowson, G., Herling, M., Humphrey, K., Boettcher, S., de Costa, C. S., Iglesias, V., Stilgenbauer, S., Gribben, J., Hallek, M., & Goede, V. (2016). Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab.

Chicago

Freeman, C. L., M. Dixon, R. Houghton, K-A Kreuzer, G. Fingerle-Rowson, M. Herling, K. Humphrey, et al. 2016. “Role of CD20 Expression and Other Pre-Treatment Risk Factors in the Development of Infusion-Related Reactions in Patients with CLL Treated with Obinutuzumab.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1223533793&authtype=sso&custid=ns315887.